MetLife Investment Management’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

MetLife Investment Management’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-36	Closed	-$91K	–	2763
2021 Q4	$91K	Hold	36	–	–	﹤0.01%	2435
2021 Q3	$661K	Hold	36	–	–	0.01%	1369
2021 Q2	$382K	Hold	36	–	–	﹤0.01%	1737
2021 Q1	$260K	Hold	36	–	–	﹤0.01%	1897
2020 Q4	$200K	Hold	36	–	–	﹤0.01%	1985
2020 Q3	$361K	Hold	36	–	–	﹤0.01%	1538
2020 Q2	$334K	Buy	36 +9	+33%	+$82.5K	﹤0.01%	1603
2020 Q1	$244K	Hold	27	–	–	﹤0.01%	1585
2019 Q4	$300K	Buy	+27	New	+$163K	﹤0.01%	1749

Other funds holding IRLA

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $23.5B AUM 33.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

MetLife Investment Management's IRLA Position: Q1 2022 in Review

MetLife Investment Management sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q1 2022, closing a stake of 36 shares — an estimated $91K sold.

MetLife Investment Management first reported a position in IRLA in Q4 2019 and held it in 9 quarters. The position peaked at $661K in Q3 2021. 85 funds tracked by Wall St. Rank hold IRLA as of Q1 2022.

MetLife Investment Management reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
MetLife Investment Management sold 36 IRulya Therapeutics Inc. Common Stock shares in Q1 2022, an estimated $91K.
MetLife Investment Management first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2019 and held it in 9 quarters.
MetLife Investment Management's IRulya Therapeutics Inc. Common Stock position peaked at $661K in Q3 2021.
85 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q1 2022.

Based on MetLife Investment Management's 13F filing for Q1 2022, filed 12 May 2022.